Expertise in
2
conditions

Hans J. Van Der Vliet

Utrecht, UT, NL 
Expertise in
2
conditions
Utrecht, UT, NL 

Overview

Hans Van Der Vliet practices practicing medicine in Utrecht, Netherlands.

Mr. Van Der Vliet is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Systemic Capillary Leak Syndrome, Opioid Induced Constipation, Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), and Pancreaticoduodenectomy.

He is actively involved in clinical research, co-authoring 102 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Utrecht, UT, Netherlands
Other Locations
Amsterdam, NH, Netherlands
Noord, NB 1081HV, Netherlands
's-hertogenbosch, NB, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor
Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor
Enrollment Status: Completed
Publish Date: March 24, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase I Open-label Clinical Trial, Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients With Advanced Solid Tumors
A Phase I Open-label Clinical Trial, Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Biological
Study Phase: Phase 1
Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer.
Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer.
Enrollment Status: Completed
Publish Date: May 10, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

102 Total Publications

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.
Journal: Journal for immunotherapy of cancer
Published: June 11, 2026

Frequently Asked Questions about Hans J. Van Der Vliet

Is Hans J. Van Der Vliet a top-rated expert for Systemic Capillary Leak Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Hans J. Van Der Vliet is classified as an Advanced expert for Systemic Capillary Leak Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hans J. Van Der Vliet participate in research or clinical trials?

Yes. Hans J. Van Der Vliet has published 102 articles and abstracts on conditions like Systemic Capillary Leak Syndrome. You can view a list of Hans J. Van Der Vliet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Der Vliet's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile